GoserelinHormone TherapySafety Rating 8/10
Primary research areaProstate cancer
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range3.6 mg monthly or 10.8 mg every 3 months SC
AdministrationSubcutaneous implant
Safety8/10 · FDA-approved (Zoladex)
NCAA D1Banned
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Goserelin
Mechanism of action
GnRH agonist implant; suppresses LH/FSH causing sex hormone castration
Safety profile
Hot flashes, bone loss, tumor flare, injection site reactions · Approved for prostate/breast cancer; hot flashes, bone loss expected; implant delivery
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Goserelin below your target.
Related pages